Additional Study Information: This study is for patients with non-alcoholic steatohepatitis (NASH) fibrosis in which there is too much fat in the liver causing inflammation and fibrosis. This condition is similar to the type of liver damage that occurs from too much alcohol use, but is not primarily caused by alcohol use. The main purpose of the study is to test whether a drug called emricasan (IDN-6556) will decrease the fat, inflammation, and fibrosis in the liver. Subjects in this study will have a 67% (2 in 3) chance of receiving emricasan and a 33% (1 in 3) chance of receiving placebo.